Cingulate Inc (CING)
0.8801
+0.04
(+4.77%)
USD |
NASDAQ |
Apr 26, 16:00
0.8946
+0.01
(+1.65%)
After-Hours: 20:00
Cingulate Cash from Financing (TTM): 9.955M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 9.955M |
September 30, 2023 | 9.050M |
June 30, 2023 | 8.117M |
March 31, 2023 | 4.899M |
December 31, 2022 | 4.899M |
Date | Value |
---|---|
September 30, 2022 | 24.90M |
June 30, 2022 | 23.37M |
March 31, 2022 | 25.19M |
December 31, 2021 | 26.54M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.899M
Minimum
Mar 2023
26.54M
Maximum
Dec 2021
15.21M
Average
9.955M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
FibroGen Inc | 122.75M |
Genprex Inc | 10.59M |
Tyra Biosciences Inc | 1.537M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |